Ash1l degraders and methods of treatment therewith
US-2024366774-A1 · Nov 7, 2024 · US
Composition for preventing or treating sepsis or septic shock comprising adk protein as active ingredient
US2016263199A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016263199-A1 |
| Application number | US-201414414366-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 7, 2014 |
| Priority date | Apr 23, 2014 |
| Publication date | Sep 15, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis -derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis -derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, and also has an excellent therapeutic effect against sepsis by enhancing viability in a sepsis animal model and suppressing inflammatory response in the lung and cell death in the spleen.
First claim
Opening claim text (preview).
1 . A pharmaceutical composition for preventing or treating sepsis or septic shock comprising an adenosine kinase (ADK) protein as an active ingredient. 2 . The pharmaceutical composition of claim 1 , wherein the ADK protein is derived from Mycobacterium tuberculosis. 3 . The pharmaceutical composition of claim 1 , wherein the ADK protein has an amino acid sequence set forth in SEQ ID NO: 1. 4 . The pharmaceutical composition of claim 1 , wherein the ADK protein is encoded by a DNA sequence set forth in SEQ ID NO: 2. 5 . The pharmaceutical composition of claim 1 , wherein the ADK protein binds to a lipopolysaccharide (LPS). 6 . A food composition for preventing or improving sepsis or septic shock comprising an ADK protein as an active ingredient.
Assignees
Inventors
Classifications
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Antibacterial agents · CPC title
Enzymes · CPC title
Adenosine kinase (2.7.1.20) · CPC title
- A61K38/45Primary
Transferases (2) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016263199A1 cover?
- The present invention relates to a composition for preventing or treating sepsis or septic shock including a Mycobacterium tuberculosis -derived adenosine kinase (ADK) protein as an active ingredient. The Mycobacterium tuberculosis -derived ADK protein according to one exemplary embodiment of the present invention has an effect of inhibit binding between the LPS and cells by binding to LPS, a…
- Who is the assignee on this patent?
- Univ Konkuk Ind Coop Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K38/45. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Sep 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).